These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Intravesical therapy for bladder cancer. Soloway MS Urol Clin North Am; 1988 Nov; 15(4):661-9. PubMed ID: 3142129 [TBL] [Abstract][Full Text] [Related]
5. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
6. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Soloway MS; Jordan AM; Murphy WM Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268 [TBL] [Abstract][Full Text] [Related]
12. [Intravesical therapy: Influence on superficial bladder cancer progression]. García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Rodríguez Robles L; Martín Benito JL; San Martín Blanco A; Regadera Sejas J Arch Esp Urol; 2007; 60(1):31-5. PubMed ID: 17408169 [TBL] [Abstract][Full Text] [Related]
13. [Prophylactic combination therapy after TUR of superficial bladder cancer]. Ao T; Uchida T; Yokoyama E; Kawakami T; Adachi K; Mashimo S; Endo T; Koshiba K Hinyokika Kiyo; 1993 Nov; 39(11):987-91. PubMed ID: 7505523 [TBL] [Abstract][Full Text] [Related]
14. [Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation]. Wang SH Zhonghua Wai Ke Za Zhi; 1992 Jul; 30(7):410-2, 443-4. PubMed ID: 1301342 [TBL] [Abstract][Full Text] [Related]
15. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269 [TBL] [Abstract][Full Text] [Related]
16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
18. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Huncharek M; McGarry R; Kupelnick B Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841 [TBL] [Abstract][Full Text] [Related]
19. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Han RF; Pan JG Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182 [TBL] [Abstract][Full Text] [Related]
20. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes]. Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]